It is better to measure apolipoproteins than traditional lipid markers in clinical routine;Bättre mäta apolipoproteiner än traditionella lipider i klinisk rutin

Lakartidningen

Volumn 103, Issue 10, 2006, Pages 753-758

  Kallner, Anders ^a   Estonius, Mats ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MALE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

APOLIPOPROTEINS A; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; LIPIDS; MALE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 33645795076     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jungner I, Walldius G. Apolipoproteiner nya och bättre riskindikatorer för hjärtinfarkt. Läkartidningen. 2004;101:1188-94.
2. Jungner I, Walldius G. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipidlowering therapy. Eur Heart J 2005;26:210-2.
3. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/Apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-medica thickness during 3 years in middle-aged men. Stroke 2004;35:2248-52
4. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-22.
5. Lamarche B, Moorjaei S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemie heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8.
6. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apoli-poprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-23.
7. Estonius M, Kallner A. How do conventional markers of lipid disorders compare with apolipoproteins? Scand J Clin Lab Invest 2005;65:33-44.
8. Information från Läkemedelsverket 2005;16(1):7-11. www.mpa.se
9. Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
10. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.
11. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173-7.